Schott Kaisha expands its vial production capacity for Covid-19 vaccine

Schott Kaisha stall at CPhI Bharat 2019

Schott Kaisha has announced an immediate investment of Rs 105 crore ( approximately EUR 12 million) into its existing facilities to increase its vial production by 300 million pieces. The decision comes at a time when drug manufacturers around the world are undergoing Covid-19 vaccine trials. Such complex medications are stored in Blazon 1 glass vials produced at Schott Kaisha plants in Gujarat and Daman.

The Indo- German language venture with the international technology group, Schott AG, plans to complete this production ramp-upwardly within a record time of 12 months. A long-term investment program and consequent infrastructure growth over the years has helped the company expand its product capabilities quickly. Over the last iii years, it had invested approximately Rs 434 crore and gear up up two new plants in Umarsadi, Gujarat, and Baddi, Himachal Pradesh. With the recently opened facility in Umarsadi, Schott Kaisha was already manufacturing over 3 billion pieces of ampoules, vials, syringes, and cartridges annually. The company is providing vaccine vials to all the fundamental vaccine developers in the country and manufacturers away.

Rishad Dadachanji, director, Schott Kaisha, said, "Pharma companies all around the world are working relentlessly to observe an effective vaccine for Covid-nineteen. As a front-runner in the pharma packaging segment, we are committed to back up the vaccine developers with the best packaging solutions. We are closely working with all our clients to supply them with vials and syringes for their vaccine trials and are continuously assessing their requirements to stay ahead of the curve."

With the looming demand surge for vaccine vials, the pharma industry relies on quality products for storing their complex drug formulations with minimal threat of contamination. Schott Kaisha has been a pioneer in the Indian marketplace to provide customizable solutions to leading pharmaceutical players worldwide. It has always given preference to a 'quality past design' arroyo, benchmark manufacturing, and quality control processes using breakthrough inspection technology, combined with best-in-course components.

The company was established in 1990 every bit a premium manufacturer of pharmaceutical containers made of neutral glass in India under the name Kaisha Manufacturers. In 2008, information technology started cooperation with the international technology group Schott. The Indo-German joint venture is a leading supplier for the pharmaceutical manufacture offer a "one finish shop" solution for the entire range of small volume tubular glass parenteral packaging, including ampoules, vials cartridges, and sterile prefillable glass syringes.

As you lot join usa today from India and elsewhere, nosotros have a favour to inquire. Through these times of ambiguity and challenge, the packaging industry in Bharat and in most parts of the earth has been fortunate. We are now read in more than ninety countries every bit our coverage widens and increases in impact. Our traffic as per analytics more than doubled in 2022 and many readers chose to support us financially even when advert fell to pieces.

As we come out of the pandemic in the adjacent few months, we hope to again expand our geography and evolve our high-bear upon reporting and authoritative and technical data, with some of the all-time correspondents in the industry. If there were ever a time to support us, it is now. You tin ability Packaging Southern asia's counterbalanced manufacture journalism and assist to sustain united states by subscribing.

Subscribe Now

vickeryhiciandold.blogspot.com

Source: https://packagingsouthasia.com/application/schott-kaisha/

Share this post